BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 16963658)

  • 1. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD.
    Guenette JA; Webb KA; O'Donnell DE
    Respir Med; 2013 May; 107(5):708-16. PubMed ID: 23421968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
    Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
    Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.
    Hanania NA; Darken P; Horstman D; Reisner C; Lee B; Davis S; Shah T
    Chest; 2003 Sep; 124(3):834-43. PubMed ID: 12970006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility.
    Bleecker ER; Emmett A; Crater G; Knobil K; Kalberg C
    Pulm Pharmacol Ther; 2008 Aug; 21(4):682-8. PubMed ID: 18541448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
    Mahler DA; Wire P; Horstman D; Chang CN; Yates J; Fischer T; Shah T
    Am J Respir Crit Care Med; 2002 Oct; 166(8):1084-91. PubMed ID: 12379552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
    Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
    Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
    Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE
    Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J;
    N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED; van Dyk M; Sagriotis A
    Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD.
    Guenette JA; Raghavan N; Harris-McAllister V; Preston ME; Webb KA; O'Donnell DE
    Respir Med; 2011 Dec; 105(12):1836-45. PubMed ID: 21917440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
    Easton PA; Hawes HG; Doig CJ; Johnson MW; Yokoba M; Wilde ER
    Chest; 2010 Mar; 137(3):558-65. PubMed ID: 19820074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
    Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.
    Dalal AA; St Charles M; Petersen HV; Roberts MH; Blanchette CM; Manavi-Zieverink K
    Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():179-87. PubMed ID: 20714371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.
    Fenton C; Keating GM
    Drugs; 2004; 64(17):1975-96. PubMed ID: 15329047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.